Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs : a systematic review and economic evaluation

Corbett, Mark orcid.org/0000-0002-5937-1493, Chehadah, Fadi, Biswas, Mousumi orcid.org/0000-0001-6781-7400 et al. (8 more authors) (2017) Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs : a systematic review and economic evaluation. Health technology assessment. pp. 1-326. ISSN 2046-4924

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © Queen’s Printer and Controller of HMSO 2017. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details.
Keywords: Psoriatic arthritis, secukinumab, Certolizumab pegol, systematic review and meta-analysis, ECONOMIC EVALUATION
Dates:
  • Accepted: 10 March 2017
  • Published: 5 October 2017
Institution: The University of York
Academic Units: The University of York > Faculty of Social Sciences (York) > Centre for Reviews and Dissemination (York)
The University of York > Faculty of Social Sciences (York) > Centre for Health Economics (York)
The University of York > Faculty of Sciences (York) > Health Sciences (York)
Depositing User: Pure (York)
Date Deposited: 09 Oct 2017 11:15
Last Modified: 14 Feb 2024 00:21
Published Version: https://doi.org/10.3310/hta21560
Status: Published
Refereed: Yes
Identification Number: https://doi.org/10.3310/hta21560

Download

Export

Statistics